Investigating methotrexate dosing and effects for Burkitt lymphoma in Malawi
Official title: Understanding Methotrexate Dosing, Pharmacokinetics, and Toxicities for Burkitt Lymphoma in Malawi
Funded at Univ of North Carolina Chapel Hill · NIH-10924460 · Data updated 2026-11-12
This study is looking to make treatments better for kids and young adults with Burkitt lymphoma by testing the safest dose of a chemotherapy drug called methotrexate and finding out how it works in the body, all while keeping an eye on how patients feel during treatment.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | June 1, 2019 |
| Project end | April 30, 2026 |
| Funding year | 2023 |
| Award (this year) | $54,000 |
| NIH project number | 3K01TW011191-05S1 |
| Project ID | NIH-10924460 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children and young adults diagnosed with Burkitt lymphoma in Sub-Saharan Africa.
✕Less likely to help
Patients with other types of cancers or those outside the age range of 0-21 years may not benefit from this research.
What this research studies
This research focuses on improving treatment for Burkitt lymphoma, a common cancer in children and young adults in Sub-Saharan Africa. The project will involve a pilot clinical trial to find the highest safe dose of methotrexate, a key chemotherapy drug. Additionally, it will develop a model to understand how the drug behaves in the body and create a tool to assess side effects from the patient's perspective. The goal is to enhance future clinical trials and treatment protocols for this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with Burkitt lymphoma.
How similar studies have gone: Similar research has shown promise in optimizing cancer treatments in resource-limited settings, indicating potential for success in this approach.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Westmoreland, Katherine Douglas — Univ of North Carolina Chapel Hill
- Study coordinator: Westmoreland, Katherine Douglas
Related research
Other NIH-funded projects on the same topics.
-
Investigating methotrexate dosing and side effects for Burkitt lymphoma in Malawi
This study is looking to make treatments better for kids and young adults with Burkitt lymphoma in Sub-Saharan Africa by testing the safest dose of a chemotherapy drug called methotrexate and finding out how it works in the body, while also listening to patients about any side effects they experience.
-
Organoid model to study how malaria and EBV drive Burkitt lymphoma in children
A study uses human tonsillar organoids to understand how malaria parasite infection and EBV together may cause a type of lymphoma in children from sub-Saharan Africa.
-
Enriching tumor-derived EBV DNA to build a diagnostic test for endemic Burkitt lymphoma (eBL)
A study to develop a blood-based test that specifically detects tumor-derived EBV DNA to improve early diagnosis of endemic Burkitt lymphoma in children.
-
Improving diagnosis of Burkitt lymphoma in children using blood tests.
This study is looking at a new way to help doctors quickly and accurately diagnose endemic Burkitt lymphoma in children by checking for a specific virus in their blood, which could lead to faster treatment and better outcomes.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.